Author

Shabana Jaynul Dewani

Observed names: S. J. Dewani, Shabana Dewani, Shabana J Dewani, Shabana J. Dewani

Institution: Columbus Oncology and Hematology Associates

Observed institutions: Wright State University, The Ohio State University Wexner Medical Center, Columbus Oncology and Hematology Associates, Dayton VA Medical Center

ORCID: 0000-0002-1622-8232

Observed ORCID: 0000-0002-1622-8232

OpenAlex ID: A5060437947

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

2021 · Ingrid A. Mayer, Fengmin Zhao, et al. · Journal of Clinical Oncology · 134

Graves’ Disease Causing Pancytopenia and Autoimmune Hemolytic Anemia at Different Time Intervals: A Case Report and a Review of the Literature

2013 · Peyman Naji, Geetika Kumar, et al. · Case Reports in Medicine · 26

All That Glitters: Sorafenib

2011 · Khurram Abbass, Shabana Dewani, et al. · Internal Medicine · 5

Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131

2024 · Karen L. Smith, Fengmin Zhao, et al. · Cancer · 3

Abstract P4-10-02: Patient-reported outcomes in EA1131: A randomized phase III trial of platinum vs. capecitabine in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy

2022 · Karen L Smith, Fengmin Zhao, et al. · Cancer Research · 2

Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial

2026 · Moriah Forster, Fengmin Zhao, et al. · JCO oncology advances. · 1

Plasmacytoma presenting as hematuria

2011 · Khurram Abbass, Shabana Dewani, et al. · International Journal of Hematology · 1

Abstract RF3-06: Tumor infiltrating lymphocytes in post-NACT residual tumors in ECOG-ACRIN EA1131 - impact of intrinsic subtypes

2026 · S. S. Badve, F. Zhao, et al. · Clinical Cancer Research

Abstract P3-01-02: Impact of race, socioeconomic status and clinicopathological features on clinical outcomes in triple negative breast cancer in the ECOG-ACRIN EA1131 trial

2025 · Moriah Forster, Fengmin Zhao, et al. · Clinical Cancer Research

Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer.

2017 · Andrew Stiff, Christopher McQuinn, et al. · Journal of Clinical Oncology

Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173).

2017 · Robert Wesolowski, Maryam B. Lustberg, et al. · Journal of Clinical Oncology

Genomic risk prediction of aromatase inhibitor-related arthralgias (AIA) in breast cancer (BC) patients using a novel analytical algorithm (NAA).

2017 · Raquel E. Reinbolt, Stephen T. Sonis, et al. · Journal of Clinical Oncology

Works count: 12

Citation count: 172

H-index: 3

I10-index: 2